YU59201A - Matrica koja se može direktno komprimovati, za kontrolisano oslobadjanje pojedinačnih dnevnih doza klaritromicina - Google Patents

Matrica koja se može direktno komprimovati, za kontrolisano oslobadjanje pojedinačnih dnevnih doza klaritromicina

Info

Publication number
YU59201A
YU59201A YU59201A YUP59201A YU59201A YU 59201 A YU59201 A YU 59201A YU 59201 A YU59201 A YU 59201A YU P59201 A YUP59201 A YU P59201A YU 59201 A YU59201 A YU 59201A
Authority
YU
Yugoslavia
Prior art keywords
clarithromycin
controlled release
daily doses
single daily
directly compressible
Prior art date
Application number
YU59201A
Other languages
English (en)
Inventor
Temeljotov Darja Ferčej
Milojka Mohar
Mateja Salobir
Barbara Rebič
Marko Opresnik
Original Assignee
LEK tovarna farmacevtskih in kemičnih izdelkov d.d.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LEK tovarna farmacevtskih in kemičnih izdelkov d.d. filed Critical LEK tovarna farmacevtskih in kemičnih izdelkov d.d.
Publication of YU59201A publication Critical patent/YU59201A/sh
Publication of RS50298B publication Critical patent/RS50298B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Pronalazak se odnosi na poboljšanu farmaceutsku formulaciju za kontrolisano oslobadjanje klaritromicina ili njegovih derivata, što je omogućeno sa novom kombinovanom matricom, koja se sastoji od masne komponente i od hidrofilne komponente, kojoj takodje mogu biti dodati surfaktant i pH modulator, kada je poželjan dodatni uticaj na profil oslobadjanja aktivne materije.
YUP-592/01A 1999-02-19 2000-02-17 Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina RS50298B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI9900039A SI20150A (sl) 1999-02-19 1999-02-19 Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina

Publications (2)

Publication Number Publication Date
YU59201A true YU59201A (sh) 2004-07-15
RS50298B RS50298B (sr) 2009-09-08

Family

ID=20432410

Country Status (21)

Country Link
EP (1) EP1150686B1 (sh)
AT (1) ATE286736T1 (sh)
AU (1) AU776912B2 (sh)
BG (1) BG65324B1 (sh)
CY (1) CY1107454T1 (sh)
CZ (1) CZ302781B6 (sh)
DE (1) DE60017361T2 (sh)
DK (1) DK1150686T3 (sh)
EE (1) EE05422B1 (sh)
ES (1) ES2235834T3 (sh)
HR (1) HRP20010684B1 (sh)
HU (1) HUP0105481A3 (sh)
PL (1) PL196665B1 (sh)
PT (1) PT1150686E (sh)
RS (1) RS50298B (sh)
RU (1) RU2237480C2 (sh)
SI (2) SI20150A (sh)
SK (1) SK287525B6 (sh)
TR (1) TR200102396T2 (sh)
UA (1) UA74778C2 (sh)
WO (1) WO2000048607A1 (sh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200000054A2 (tr) * 2000-01-05 2001-08-21 Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇ Klaritromisin içeren sürekli salım sağlayan tablet formülasyonları.
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
IN192748B (sh) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6673369B2 (en) 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
CA2405918A1 (en) * 2001-10-01 2003-04-01 Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
SE0103369D0 (sv) * 2001-10-09 2001-10-09 Astrazeneca Ab Pharmaceutical formulation
CA2465405A1 (en) 2001-11-02 2003-05-08 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
AU2003214506A1 (en) * 2002-04-03 2003-10-13 Ranbaxy Laboratories Limited Clarithromycin formulations having improved bioavailability
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
AU2003256848A1 (en) * 2002-07-29 2004-02-16 Alza Corporation Formulations and dosage forms for controlled delivery of topiramate
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005023221A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Clarithromycin formulations having improved biovailability
US7943585B2 (en) * 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
WO2005102289A1 (en) * 2004-03-24 2005-11-03 Lupin Limited Clarithromycin extended release formulation
EP2283824B1 (en) 2009-07-30 2017-04-19 Special Products Line S.p.A. Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) * 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60163823A (ja) * 1984-02-03 1985-08-26 Taisho Pharmaceut Co Ltd 経口投与製剤
JPS60214796A (ja) * 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS63188621A (ja) * 1987-01-30 1988-08-04 Taisho Pharmaceut Co Ltd 矯味経口製剤
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
IL87219A0 (en) * 1987-08-07 1988-12-30 Abbott Lab Erythromycin formulations for oral administration
JP2553882B2 (ja) * 1987-08-08 1996-11-13 富士写真光機株式会社 走査結像光学系
US5599556A (en) * 1991-12-31 1997-02-04 Abbott Laboratories Prolamine coatings for taste masking
CA2182282C (en) * 1994-02-16 2006-04-18 Jacqueline E. Briskin Process for preparing fine particle pharmaceutical formulations

Also Published As

Publication number Publication date
HUP0105481A2 (hu) 2002-05-29
RU2237480C2 (ru) 2004-10-10
CZ20012964A3 (cs) 2002-01-16
BG65324B1 (bg) 2008-02-29
DE60017361D1 (de) 2005-02-17
SK287525B6 (sk) 2011-01-04
DK1150686T3 (da) 2005-04-04
HUP0105481A3 (en) 2003-04-28
PT1150686E (pt) 2005-05-31
PL196665B1 (pl) 2008-01-31
UA74778C2 (en) 2006-02-15
CZ302781B6 (cs) 2011-11-02
ES2235834T3 (es) 2005-07-16
WO2000048607A1 (en) 2000-08-24
EE200100433A (et) 2002-12-16
EP1150686B1 (en) 2005-01-12
HRP20010684A2 (en) 2002-10-31
DE60017361T2 (de) 2005-12-22
CY1107454T1 (el) 2012-12-19
HRP20010684B1 (en) 2011-01-31
SK11972001A3 (sk) 2002-02-05
EE05422B1 (et) 2011-06-15
SI1150686T1 (en) 2005-06-30
ATE286736T1 (de) 2005-01-15
PL350419A1 (en) 2002-12-16
BG105914A (bg) 2002-05-31
RS50298B (sr) 2009-09-08
AU2704900A (en) 2000-09-04
TR200102396T2 (tr) 2002-01-21
AU776912B2 (en) 2004-09-23
EP1150686A1 (en) 2001-11-07
SI20150A (sl) 2000-08-31

Similar Documents

Publication Publication Date Title
YU59201A (sh) Matrica koja se može direktno komprimovati, za kontrolisano oslobadjanje pojedinačnih dnevnih doza klaritromicina
BR0012046A (pt) Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória
AR035550A1 (es) Composiciones estables biocidas
ATE219659T1 (de) Verwendung gelierbarer pharmazeutischer zusammensetzungen in der parodontologie
YU49202A (sh) Benzazolski derivati i njihova upotreba kao modulatora jnk
YU87101A (sh) Derivati benzena, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže
BRPI0417043A (pt) composição farmacêutica, forma de dosagem sólida, método de manufatura de forma de dosagem sólida, e, uso da composição
FR2811552B1 (fr) Composition notamment cosmetique ou pharmaceutique se presentant sous forme solide
BR0112417A (pt) Composições farmacêuticas contendo composto dds
BR0211736A (pt) Formulação para suspensão oral estabilizada
BR0011860A (pt) Composições antibacterianas e processo para redução de uma população de bactérias sobre uma superfìcie
BR0015256A (pt) Composições farmacêuticas contendo uma droga de antibiótico de fluoroquinolona e uma goma de xantano
NO20021859L (no) Nye oligosakkarider, deres fremstilling samt farmasöytiske preparater inneholdende oligosakkaridene
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
BR0111678A (pt) Composições medicinais contendo derivados de propenona
HRP20020298B1 (en) Pharmaceutical solutions of levosimendan
BR9408023A (pt) Formulações de fenbendazol
BR0316108A (pt) Derivados de fenilalquil e piridilalquil piperazina e composição farmacêutica compreendendo os mesmos
HRP20030907B1 (en) Pharmaceutical composition based on macrolides for topical application in ophthalmology
FR2686513B1 (fr) Compositions pharmaceutiques aqueuses de cromoglycate sodique.
ES2176786T3 (es) Uso de extractos de ginkgo biloba para la preparacion de composicionesfarmaceuticas.
DK0973505T3 (da) Vandigt farmaceutisk præparat, der omfatter en aktiv ingrediens, som er meget tungt opløselig i vand
RS50033B (sr) Derivati etansulfonil-piperidina
ATE286395T1 (de) Antithrombotische mittel
HN2000000090A (es) Sal difosfato de un derivado de 4sustituido-9-desoxo-9a-aza-9a-homoeritromicina y su composicion farmaceutica.